Market Overview Cancer rates could further increase by 50%, to 15 million new cases, by 2020, as per the World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners can prevent as many as one-third of cancers, worldwide. The American Cancer Society, estimated in 2016, that there were 1,685,210 new cancer cases and about 595,690 deaths due to cancer, in the United States. The National Cancer Institute reported that more than 60% of the world’s new cancer cases occur in Africa, Asia, and Central and South America. About 70% of the worldwide deaths due to cancer occur in these regions.
According to the WHO, almost 70% of deaths from cancer occur in low and middle-income countries, and only one in five low- and middle-income countries has the necessary data to drive cancer-related policies. This worldwide and extensive threat of cancer remains a major driver for the development of new cancer therapies that help in risk assessment, early diagnosis, and effective monitoring of the treatment.
Cancer resistance to treatment is a major obstacle. However, epigenetic drugs, on their own or in combination with other drugs, can be a viable alternative. The epigenetic drug used in the laboratory study stops the ability of cancer cells to hide from the immune system and makes the tumor vulnerable. So, increasing prevalence of cancer will augment the growth of the epigenetics market.
Scope of the Report As per the scope of this report, epigenetics, in simple terms, refers to the study of genetic effects that are not entirely encoded by the DNA sequence of an organism. Epigenetics mainly deals with gene expression. Epigenetics also refers to changes in the genome in terms of functionality, which do not involve a change in the nucleotide sequence. The DNA methylation or histone modification is a type of mechanism that causes epigenetic changes.
Key Market Trends By Technology Segment, DNA methylation is Expected to Hold Largest Share Over the forecast period
DNA methylation dominated the global epigenetics market as it is covalent addition of a methyl group in cytosine ring, which leads to inhibition of transcription. Sensitive bisulfite modification followed by PCR is called methylation sensitive PCR (MSP). Real-time PCR for methylation detection, methyl light, and quantitative analysis of methylated alleles are variations of MSP. Currently, quantitative methods such as allele-specific bisulphite sequencing, southern-based method, bisulphite pyrosequencing, and bisulphite PCR followed by MALDI - TOF MS are also useful for DNA methylation. Advancements in technologies are increasingly enabling assessment of locus-specific DNA methylation on a genome wide scale.
North America Region Holds the Largest Market Share of Epigenetics Market
North America dominates the epigenetics market, owing to rapid developments in healthcare infrastructure, the presence of major players in the region, huge investments made in the research and development. With increasing investments being made in the R&D of products by industries, an increase in the demand for protein expression systems is expected, as many mammalian proteins, such as growth hormone, insulin, antibodies, and vaccines are produced industrially. In recent years, biopharmaceutical sales have reached 30% of all new pharmaceutical sales in the country. The United States accounts for the world’s largest expenditure on healthcare research. All these factors will augment the growth of the studied market.
Competitive Landscape The market competition is set to intensify as several key players are focusing on the expansion of their epigenetics portfolio through acquisition and collaboration with companies. The epigenetics market is expected to open up several opportunities for new players as well as currently established market leaders.
Reasons to Purchase this report: - The market estimate (ME) sheet in Excel format
- Report customization as per the client’s requirements
- 3 months of analyst support
Our reports have been used by over 10K customers, including:
269 pages •
By The Business Research Company
• Aug 2021
Anatomic Pathology Equipment and Consumables Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists, marketers and senior management with the critical information they need to assess the global anatomic pathology equipment and consumables market as it emerges from the COVID 19 shut down. Description: Where...
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
The Middle East & Africa organoids market is expected to reach US$ 141.26 million in 2027 from US$ 37.34 million in 2019; the market is estimated to grow at a CAGR of 20.9% from 2020 to 2027. The growth of the market can be attributed to growing research on organoids in the Middle East & Africa region and rising focus on developing alternatives...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
Anatomic pathology market to register a CAGR of 7.1% from 2020 to 2025. The global anatomic pathology market size is projected to reach a value of USD 46.8 billion by 2025 from USD 33.3 billion in 2020, at a CAGR of 7.1% during the forecast period. The growth in this market is attributed to the high incidence of cancer...
Certain factors that are driving the market growth include the increased incidence of cancer, globally, and higher acceptance of treatments for cancer in the developing regions, the paradigm shift in healthcare, from disease diagnosis to risk assessment or early diagnosis, and increasing usage of biomarkers in drug development. - Globally,...
The anti-venom market is expected to register a CAGR of nearly 4.7% during the forecast period, 2019-2024.
- Snakebite is a neglected public health issue in many tropical and subtropical countries. About 5 million snake bites occur each year, resulting in up to 2.5 million envenoming’s (poisoning...
Research And Development
Infectious Disease Mortality
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.